PsyBio Therapeutics Corp. (PSYBF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -4.52 Million USD | 44.39% |
| 2021 | - USD | -2331037.11% |
| 2020 | - USD | 100.91% |
| 2019 | -16.15 Thousand USD | -86.83% |
| 2018 | -20.86 Thousand USD | 47.65% |
| 2017 | -39.84 Thousand USD | 48.27% |
| 2016 | -77.03 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -763.45 Thousand USD | 16.02% |
| 2023 Q2 | -156.99 Thousand USD | 79.44% |
| 2022 Q2 | -1.34 Million USD | 6.77% |
| 2022 Q4 | -909.13 Thousand USD | -2.79% |
| 2022 FY | - USD | 44.39% |
| 2022 Q1 | -1.43 Million USD | 29.24% |
| 2022 Q3 | -884.46 Thousand USD | 34.12% |
| 2021 FY | - USD | -2331037.11% |
| 2021 Q1 | -1.4 Million USD | -2122.39% |
| 2021 Q2 | -3.82 Million USD | -172.01% |
| 2021 Q3 | -2.32 Million USD | 39.21% |
| 2021 Q4 | -2.03 Million USD | 12.47% |
| 2020 Q2 | -24.52 Thousand USD | -2375.42% |
| 2020 FY | - USD | 100.91% |
| 2020 Q4 | 69.52 Thousand CAD | 22049.8% |
| 2020 Q3 | 313.89 USD | 101.28% |
| 2020 Q1 | -990.62 USD | 90.61% |
| 2019 Q4 | -10.55 Thousand CAD | 0.0% |
| 2019 FY | - USD | -86.83% |
| 2018 FY | - USD | 47.65% |
| 2017 FY | - USD | 48.27% |
| 2016 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 93.628% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 23.659% |
| SQZ Biotechnologies Company | -64.14 Million USD | 92.943% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 73.942% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 104.813% |
| Mesoblast Limited | -62.38 Million USD | 92.745% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -194.665% |
| Genus plc | 73.7 Million USD | 106.141% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 31.541% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -27.606% |
| Marizyme, Inc. | -34.28 Million USD | 86.797% |
| ContraFect Corporation | -64.99 Million USD | 93.037% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 48.402% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -222.883% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -71.158% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -94.774% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -773.705% |
| Accustem Sciences Inc. | -3.74 Million USD | -20.814% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 90.615% |
| EV Biologics, Inc. | -1.26 Million USD | -257.2% |
| Q BioMed Inc. | -617.62 Thousand USD | -632.835% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 226.713% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -615.71% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -98.127% |
| Biomind Labs Inc. | -1.03 Million USD | -337.504% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 145.826% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 36.796% |
| Skye Bioscience, Inc. | -13.54 Million USD | 66.59% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -204.3% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -18004.78% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -16.525% |
| IMV Inc. | -35.52 Million USD | 87.259% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 71.479% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -80.906% |
| GB Sciences, Inc. | -1.41 Million USD | -218.772% |
| Alpha Cognition Inc. | -9.7 Million USD | 53.365% |
| HST Global, Inc. | -5303.00 USD | -85251.593% |
| CSL Limited | 4.78 Billion USD | 100.095% |
| Halberd Corporation | -74.27 Thousand USD | -5993.506% |
| Enzolytics Inc. | -2.12 Million USD | -113.296% |
| Resverlogix Corp. | -11.74 Million USD | 61.453% |
| Affymax, Inc. | -14.29 Million USD | 68.337% |
| SYBLEU INC | -141.57 Thousand USD | -3097.12% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -47.769% |
| argenx SE | -216.02 Million USD | 97.905% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 91.821% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 471.914% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -201.967% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1294.738% |
| AVAX Technologies, Inc. | -6.11 Million USD | 25.954% |
| Zenith Capital Corp. | -8.6 Million USD | 47.407% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.18% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -25881.258% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -85.01% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -2471.346% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 88.581% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -56.49% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -332.586% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 67414.024% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -158.64% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -135.628% |
| BioStem Technologies, Inc. | -7.55 Million USD | 40.079% |
| ONE Bio Corp. | 13.61 Million USD | 133.249% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -2399.445% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -120.039% |
| Agentix Corp. | -1.37 Million USD | -229.956% |
| LadRx Corporation | 412.28 Thousand USD | 1197.837% |
| Cell Source, Inc. | -4.27 Million USD | -5.937% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1132.553% |
| Regen BioPharma, Inc. | 1.46 Million USD | 408.754% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -383.078% |
| NovAccess Global Inc. | -1.03 Million USD | -337.399% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 151.121% |
| Itoco Inc. | -1.86 Million USD | -142.173% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1092.296% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -305.573% |
| Kadimastem Ltd | -2.62 Million USD | -72.467% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1792.618% |
| CytoDyn Inc. | -18.02 Million USD | 74.895% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -5627.258% |
| Mobile Lads Corp. | -2.24 Million USD | -101.958% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -36911.98% |
| Qrons Inc. | -40.08 Thousand USD | -11192.62% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -831.933% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 958.155% |
| Rebus Holdings, Inc. | -951 Thousand USD | -375.941% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -326.191% |
| International Stem Cell Corporation | 202 Thousand USD | 2340.691% |
| Bioxytran, Inc. | -3.82 Million USD | -18.482% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -8498.395% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -83.847% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 87.381% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -9958.211% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -65.31% |
| Neutra Corp. | -181.24 Thousand USD | -2397.252% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 77.548% |
| PureTech Health plc | -11.62 Million USD | 61.072% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 77.546% |
| IXICO plc | -707 Thousand USD | -540.197% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 41.104% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 90.638% |
| CSL Limited | 4.73 Billion USD | 100.096% |
| Cellectis S.A. | -92.63 Million USD | 95.114% |